【华人健康：拟1.33亿元收购扬祖惠民46.01%股权】华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。

金融界2025-05-21

华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537935573?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-21 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537935573","market":"sh","top_or_hot":-1,"title":"【华人健康：拟1.33亿元收购扬祖惠民46.01%股权】华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。","media":"金融界","content":"<div>\n<p>华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/21211350575759.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【华人健康：拟1.33亿元收购扬祖惠民46.01%股权】华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【华人健康：拟1.33亿元收购扬祖惠民46.01%股权】华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-21 21:13 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/05/21211350575759.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/21211350575759.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301408","symbol_name":"华人健康","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/21211350575759.shtml","article_id":"2537935573","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537935573","pubTimestamp":1747833211,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","301408":"华人健康","BK1161":"生物科技","BK0209":"零售","BK1515":"抗疫概念","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"[Chinese Health: plans to acquire 46.01% equity of Yangzu Huimin for 133 million yuan] Chinese Health announced that the company plans to purchase 46.01% equity of Yangzu Huimin at a price of 133 million yuan and 46.01% equity of Haihua Pharmaceutical at a price of 125 million yuan, and purchase 70.01% equity of Tonglu Yishengtang at a price of 68.2598 million yuan. After the completion of this transaction, the target company will be included in the scope of the company's consolidated statements. The company plans to use its own funds and change the use of part of the raised funds for payment.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"301408":1,"09939":1},"content_text":"华人健康公告，公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购买海华医药46.01%的股权，以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后，目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付，若变更募集资金用途的审核未获批准，将全部使用自有资金支付。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537935573","isCrawlerRequest":true}